Clinical Trials on Meningococcal Infection (Healthy Volunteers)

Total 4554 results

GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years

Infections, Meningococcal

Lebanon
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

Infections, Meningococcal

United States, Canada
GlaxoSmithKline

Completed

Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old

Infections, Meningococcal

Austria, Greece
GlaxoSmithKline

Completed

Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration

Infections, Meningococcal

Taiwan, Mexico
GlaxoSmithKline

Completed

N. Meningitidis Carriage Study

Infections, Meningococcal

Philippines
GlaxoSmithKline

Completed

Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects

Infections, Meningococcal

United States, Czechia
GlaxoSmithKline

Completed

Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs

Infections, Meningococcal

Denmark
University of British Columbia
Canadian Institutes of Health Research (CIHR)

Completed

Evaluation of Meningococcal C Vaccine Programmes in Canadian Children

Meningococcal Sero-type C Infection

Canada
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
GlaxoSmithKline

Completed

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

Meningococcal Disease

Korea, Republic of
Novartis Vaccines

Completed

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Meningococcal Disease

United States, Poland
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Meningococcal Disease

Italy
Novartis Vaccines

Completed

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Meningococcal Disease

Austria, Finland, Germany, Italy, Czech Republic
Leiden University Medical Center

Completed

Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines

Meningococcal Disease

Netherlands
Hartford Hospital
Merck Sharp & Dohme LLC

Completed

Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

Diabetes | Healthy Volunteers | Wound Infection

United States
Public Health England

Completed

PRIME Follow up - Quadri Meningo Vacinees (PRIMEfollowup)

Meningococcal Disease
University of Adelaide
SA Health

Completed

South Australian Meningococcal B Vaccine Herd Immunity Study (B Part of It)

Meningococcal Disease

Australia
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

Meningococcal Disease

Chile
Novartis Vaccines

Withdrawn

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older

Meningococcal Disease
Novartis Vaccines
Novartis

Completed

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Meningococcal Disease

United Kingdom
Novartis Vaccines

Completed

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

Meningococcal Disease

United States, Australia, Canada
Novartis Vaccines

Completed

Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years

Meningococcal Disease | Meningococcal Meningitis

Italy
GlaxoSmithKline

Active, not recruiting

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Infections, Meningococcal

United States, Australia, Finland, Poland, Belgium, Brazil, Sweden, Turkey
GlaxoSmithKline

Completed

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine

Infections, Meningococcal

Philippines, Saudi Arabia
GlaxoSmithKline

Completed

Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years

Infections, Meningococcal

Philippines
GlaxoSmithKline

Completed

Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612

Infections, Meningococcal

Sweden, Denmark
GlaxoSmithKline

Completed

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612

Infections, Meningococcal

Philippines, India
GlaxoSmithKline

Completed

Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine

Infections, Meningococcal

Germany, Austria
GlaxoSmithKline

Completed

Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs

Infections, Meningococcal

Belgium
GlaxoSmithKline

Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

Infections, Meningococcal

United States
Hoffmann-La Roche

Completed

A Prospective Study to Evaluate the Specificity of the Cobas TaqScreen MPX Test for Use on the Cobas s 201 System for Screening Plasma Pools From Source Plasma Donors for the Presence of HBV DNA, HCV RNA, and HIV-1 RNA

Healthy Volunteer

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Tetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)

Canada
APR Applied Pharma Research s.a.

Recruiting

Study on Performance and Safety of Sentinox in the Prevention of Acute Respiratory Infections (ARI)

Healthy Volunteers

Italy
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Healthy Volunteers | Respiratory Syncytial Virus Infection | Human Metapneumovirus

United States, Puerto Rico
Tibotec Pharmaceuticals, Ireland

Completed

TMC649128HPC1001 - First In-human Trial to Examine Safety, Tolerability, and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses of TMC649128 in Healthy Volunteers

Healthy Volunteer
Johns Hopkins Bloomberg School of Public Health
United States Department of Defense; Naval Medical Research Center

Completed

Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge

Healthy Volunteer

United States
National Institute of Diabetes and Digestive and...

Recruiting

Food Intake Response to Short-Term Modifications of Metabolism in Humans

Healthy Volunteers

United States
Charité Research Organisation GmbH
Bayer

Completed

Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat (NIC-002)

Healthy Volunteers

Germany
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

Healthy Volunteers

United States
University of Lausanne Hospitals

Completed

Immunogenicity and Safety of the Seasonal Flu Vaccine in Elderly and in SOT Recipients

Healthy Volunteers

Switzerland
Biogen

Completed

A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers

Healthy Volunteers

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Characterization of the Innate Immune Response in Healthy NIH Employees at Baseline and After Immunization With the H1N1 Vaccine

Healthy Volunteers

United States
Poitiers University Hospital

Recruiting

Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease (CARACIIM)

Meningococcal Infections

France
GlaxoSmithKline

Completed

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Meningococcal Disease

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

Meningococcal Disease

Italy
Novartis Vaccines

Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Meningococcal Disease

Finland, Czech Republic
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Meningococcal Disease

United Kingdom
Novartis Vaccines
Novartis

Completed

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

Meningococcal Disease

Canada, United Kingdom
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

Meningococcal Disease

United Kingdom

3

Subscribe